These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1513919)

  • 21. Polymorphic oxidation of debrisoquine in women with breast cancer.
    Ladero JM; Benítez J; Jara C; Llerena A; Valdivielso MJ; Muñoz JJ; Vargas E
    Oncology; 1991; 48(2):107-10. PubMed ID: 1997931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative polymorphism of debrisoquine in Parkinson's disease.
    Benitez J; Ladero JM; Jimenez-Jimenez FJ; Martinez C; Puerto AM; Valdivielso MJ; Llerena A; Cobaleda J; Muñoz JJ
    J Neurol Neurosurg Psychiatry; 1990 Apr; 53(4):289-92. PubMed ID: 2341841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
    Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
    Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
    Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
    Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.
    Cerqueira PM; Mateus FH; Cesarino EJ; Bonato PS; Lanchote VL
    J Chromatogr B Biomed Sci Appl; 2000 Dec; 749(2):153-61. PubMed ID: 11145052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.
    Siegmund W; Fengler JD; Franke G; Zschiesche M; Eike O; Eike E; Meisel P; Wulkow R
    Br J Clin Pharmacol; 1991 Oct; 32(4):467-72. PubMed ID: 1958441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
    Eichelbaum M; Bertilsson L; Küpfer A; Steiner E; Meese CO
    Br J Clin Pharmacol; 1988 Apr; 25(4):505-8. PubMed ID: 3382592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphic debrisoquin metabolism in a Turkish population.
    Bozkurt A; Basci NE; Isimer A; Sayal A; Kayaalp SO
    Clin Pharmacol Ther; 1994 Apr; 55(4):399-401. PubMed ID: 8162666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relationship between amitriptyline metabolism and polymorphic debrisoquine hydroxylation in native Chinese volunteers].
    Zhang XH; Yu P; Gu NF; Yin JL; Jiang WD
    Yao Xue Xue Bao; 1993; 28(2):85-91. PubMed ID: 8328289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.
    Islam SI; Idle JR; Smith RL
    Xenobiotica; 1980 Nov; 10(11):819-25. PubMed ID: 7467397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Debrisoquine oxidation in an Italian population: a study in healthy subjects and in schizophrenic patients.
    Spina E; Campo GM; Calandra S; Caputi AP; Carrillo JA; Benitez J
    Pharmacol Res; 1992 Jan; 25(1):43-50. PubMed ID: 1738757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.
    Kallio J; Huupponen R; Seppälä M; Säkö E; Iisalo E
    Br J Clin Pharmacol; 1990 Oct; 30(4):638-43. PubMed ID: 1981321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.
    Ladero JM; Benítez J; González JF; Vargas E; Díaz-Rubio M
    Eur J Clin Pharmacol; 1991; 40(5):525-7. PubMed ID: 1884729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphic 2-hydroxylation of desipramine. A population and family study.
    Dahl ML; Iselius L; Alm C; Svensson JO; Lee D; Johansson I; Ingelman-Sundberg M; Sjöqvist F
    Eur J Clin Pharmacol; 1993; 44(5):445-50. PubMed ID: 8359181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
    Pereira VA; Auler JO; Carmona MJ; Mateus FH; Lanchote VL; Breimer DD; Santos SR
    Braz J Med Biol Res; 2000 May; 33(5):509-14. PubMed ID: 10775881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic cytochrome P450-mediated oxidation function in migraine.
    Amery WK; Davies PT; Caers LI; Heykants J; Steiner TJ; Woestenborghs R; Rose FC
    Cephalalgia; 1988 Jun; 8(2):71-4. PubMed ID: 3401919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidation phenotyping in Chinese and Malay populations.
    Lee EJ; Nam YP; Hee GN
    Clin Exp Pharmacol Physiol; 1988 Nov; 15(11):889-91. PubMed ID: 3229012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.
    Siegmund W; Hanke W; Zschiesche M; Franke G; Biebler KE; Wilke A
    Int J Clin Pharmacol Ther Toxicol; 1990 Dec; 28(12):504-9. PubMed ID: 2086491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidative polymorphism of debrisoquine is not related to the risk of Alzheimer's disease.
    Benítez J; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Ladero JM
    J Neurol Sci; 1993 Jul; 117(1-2):8-11. PubMed ID: 8410072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.